Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psoriasis induced by interferon-alpha.

J Funk1, T Langeland, E Schrumpf

  • 1Department of Dermatology, Rikshospitalet, Oslo, Norway.

The British Journal of Dermatology
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid antigens in bile from patients with chronic liver diseases activate natural killer T cells.

Clinical and experimental immunology·2020
Same author

Natural killer T cells mediate inflammation in the bile ducts.

Mucosal immunology·2018
Same author

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.

European journal of cancer (Oxford, England : 1990)·2018
Same author

Long-term efficacy of combined phacoemulsification plus trabeculectomy versus phacoemulsification plus excimer laser trabeculotomy.

Klinische Monatsblatter fur Augenheilkunde·2017
Same author

Secondary Osteoporosis in Liver Transplant Recipients: a Longitudinal Study in Patients With and Without Cholestatic Liver Disease.

Scandinavian journal of gastroenterology·2017
Same author

Dose-response relationship of temozolomide, determined by the Pig-a, comet, and micronucleus assay.

Archives of toxicology·2017
Same journal

Does loss of chromosome Y in blood contribute to the sex disparity of dermatitis and eczema at older ages?

The British journal of dermatology·2026
Same journal

Soluble CD83 reverses alopecia areata via IDO-mediated Treg cell activation.

The British journal of dermatology·2026
Same journal

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

The British journal of dermatology·2026
Same journal

Clinicopathological features of lymphocytic thrombophilic arteritis and the relationship with livedoid vasculopathy - a case series of 36 patients.

The British journal of dermatology·2026
Same journal

Improving Prognostication for Cutaneous Squamous Cell Carcinoma.

The British journal of dermatology·2026
Same journal

Recurrent and novel GLTP variants in five patients with nonsyndromic epidermal differentiation disorder: phenotypic and genotypic expansion.

The British journal of dermatology·2026
See all related articles

Recombinant human interferon-alpha (IFN-alpha) therapy for cancer may trigger or worsen psoriasis in some patients. Dosage may correlate with psoriasis severity, suggesting a link between IFN-alpha treatment and skin condition onset or exacerbation.

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Recombinant human interferon-alpha (IFN-alpha) is utilized in treating various cancers.
  • Previous reports suggest IFN-alpha may exacerbate or induce psoriasis onset.

Observation:

  • This study reports on four cancer patients treated with IFN-alpha (2b or 2a).
  • Three patients developed new-onset psoriasis, and one experienced aggravation of existing psoriasis during IFN-alpha treatment.
  • The patients had carcinoid syndrome or renal carcinoma, receiving doses from 1.5 million to 18 million units.

Findings:

  • IFN-alpha treatment was associated with the development or worsening of psoriasis in all four cases.
  • A potential correlation between psoriasis severity and IFN-alpha dosage was observed in two patients.

Related Experiment Videos

  • This highlights a significant dermatological side effect of IFN-alpha therapy.

    • Implications:

    • Clinicians should be aware of the potential for IFN-alpha to induce or exacerbate psoriasis.
    • Monitoring for dermatological adverse events is crucial in cancer patients undergoing IFN-alpha treatment.
    • Further research may elucidate the mechanisms underlying IFN-alpha-induced psoriasis and inform risk management strategies.